PYR-41 and Thalidomide Impair Dendritic Cell Cross-Presentation by Inhibiting Myddosome Formation and Attenuating the Endosomal Recruitments of p97 and Sec61 via NF-κB Inactivation

Figure 10

Mechanism of PYR-41- and thalidomide-impaired DC cross-presentation. PYR-41 and thalidomide inhibit myddosome formation via reducing NF-κB activation. Decreased myddosome formation recruited less p97 and Sec61 from the ER toward the endosomes, leading to less internalized antigens exported to the cytosol to be degraded, resulting in a reduced cross-presentation and subsequent cross-priming.